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Background: Acute abdominal pain (AAP) comprises up to 10% of all emergency depart-
ment (ED) visits. Current pain management practice is moving toward multi-modal analgesia 
regimens that decrease opioid use.
Objective: This project sought to determine whether, in patients with AAP (population), does 
administration of butyrophenone antipsychotics (intervention) compared to placebo, usual care, 
or opiates alone (comparisons) improve analgesia or decrease opiate consumption (outcomes)?
Methods: A structured search was performed in Cochrane CENTRAL, CINAHL, Database of 
Abstracts of Reviews of Effects, Directory of Open Access Journals, Embase, IEEE-Xplorer, 
Latin American and Caribbean Health Sciences Literature, Magiran, PubMed, Scientific Infor-
mation Database, Scopus, TÜBİTAK ULAKBİM, and Web of Science. Clinical trial registries 
(ClinicalTrials.gov, World Health Organization International Clinical Trials Registry Platform, 
and Australian New Zealand Clinical Trials Registry), relevant bibliographies, and conference 
proceedings were also searched. Searches were not limited by date, language, or publication 
status. Studies eligible for inclusion were prospective randomized clinical trials enrolling 
patients (age ≥18 years) with AAP treated in acute care environments (ED, intensive care unit, 
postoperative). The butyrophenone must have been administered either intravenously or intra-
muscularly. Comparison groups included placebo, opiate only, corticosteroids, non-steroidal 
anti-inflammatory drugs, or acetaminophen.
Results: We identified 7,217 references. Six studies met inclusion criteria. One study assessed 
ED patients with AAP associated with gastroparesis, whereas five studies assessed patients with 
postoperative AAP: abdominal hysterectomy (n=4), sleeve gastrectomy (n=1). Three of four studies 
found improvements in pain intensity with butyrophenone use. Three of five studies reported no 
change in postoperative opiate consumption, while two reported a decrease. One ED study reported 
no change in patient satisfaction, while one postoperative study reported improved satisfaction 
scores. Both extrapyramidal side effects (n=3) and sedation (n=3) were reported as unchanged.
Conclusion: Based on available evidence, we cannot draw a conclusion on the efficacy or 
benefit of neuroleptanalgesia in the management of patients with AAP. However, preliminary 
data suggest that it may improve analgesia and decrease opiate consumption.
Keywords: neuroleptanalgesia, butryophenone, abdominal pain, haloperidol, droperidol
Background
Description of the condition
Acute abdominal pain (AAP): emergency medicine
AAP is one of the most common chief complaints of patients in the emergency depart-
ment (ED), constituting 6%–10% of all visits,1,2 and the incidence is rising.3 The average 
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ED length-of-stay (LOS) is over 6 hours, with admission rates 
approaching 25%.1,2 The majority (44%–59%) of patients are 
treated with an opiate/opioid analgesic, with morphine being 
the single most commonly administered analgesic (20%).4,5 
In addition, inadequate pain management (oligoanalgesia) in 
the ED is a common problem.6 Only 50%–66% of ED patients 
with abdominal pain receive analgesia.3,4,7–9 Average analgesia 
wait times vary considerably, with one study reporting mean 
analgesia wait times of 4.1 hours for mild pain, 1.85 hours 
for moderate pain, and 1.37 hours for severe pain.10 This 
time to analgesia may itself be longer than the entire mean 
ED LOS for all comers.2,3,11 Timely analgesic administra-
tion has been shown to improve patient care and reduced 
ED LOS.12 Many factors contribute to ED oligoanalgesia, 
including the myth that early analgesia delays diagnosis of 
abdominal pain, despite evidence to the contrary.13–15 Com-
monly administered opioid analgesics also create a range 
of problems, from underuse (oligoanalgesia/opiophobia) 
and undesirable side effects to misuse (opioid crisis).16 A 
concerning observation is that 25% of AAP patients treated 
with an opioid are discharged with a prescription for one. 
Current pain management practice is moving toward recent 
United States Food and Drug Administration (US FDA) goals 
that emphasize adequate pain control with increased use of 
multimodal pain regimens and decreased opioid use.17 Insuf-
ficient data regarding the efficacy of alternative regimens and 
their side effect profiles have hampered efforts to move away 
from heavy opiate regimens.18,19
AAP: postoperative
According to data from the US Agency for Healthcare 
Research and Quality, 6 of the 15 most common operating 
room procedures performed during hospital stays in 2012 
were abdominal procedures, including 1) cholecystectomy 
and common duct exploration, 2) hysterectomy (abdominal 
and vaginal), 3) colorectal resection, 4) excision, lysis of 
peritoneal adhesions, 5) appendectomy, and 6) oophorectomy 
(unilateral and bilateral).20 These accounted for accounting 
for 1.85 million hospital stays.20 Evidence suggests that post-
operative patients frequently need less opiates on discharge 
than that are prescribed, leaving excess opioid for potential 
diversion.21–23 Moreover, 5% of young adults continue to 
receive opioid refills long after surgery.24 Studies have demon-
strated that opioid sparing postoperative analgesia techniques 
may be effective following abdominal surgery. For example, 
treatment with acetaminophen (1,000 mg intravenous [IV] 
every 6 hours or 650 mg IV every 4 hours) or non-steroidal 
agents has been shown to lower opioid consumption and the 
need for rescue medication following abdominal surgery, with 
greater effects demonstrated by combining these agents.25–27 
In addition, IV lidocaine has been shown to hasten patient 
rehabilitation and shorten hospital stays following abdominal 
surgery.28 Dipyrone (metamazol) has been shown to have opi-
ate sparing effects for abdominal pain in the postoperative 
setting.29 It remains unclear which (if any) opioid sparing 
postoperative analgesia regimens alter postoperative opioid 
requirements post-discharge.
Description of the intervention
How the intervention might work
Neuroleptanalgesia involves combining an opiate with a 
neuroleptic drug (eg, haloperidol and droperidol) for anal-
gesia. The most commonly used neuroleptics in the USA 
are butyrophenones. Butyrophenones are a subclass of 
neuroleptic antipsychotic drugs. Haloperidol, which was 
introduced in 1957 and was approved by the US FDA in 
1967, is a derivative of meperidine (Demerol) and is the 
most widely used butyrophenone in the USA. Although once 
widely used, droperidol (introduced in 1961, FDA approved 
in 1970) is now unavailable due to a black box warning and 
drug shortages. A complete list of butyrophenone medica-
tions is listed in Table 1. Benperidol is available in Europe 
only, and azaperone is approved for use in veterinary settings 
only at this time.
Haloperidol is a first-generation antipsychotic that exerts 
its effects via non-selectively blocking postsynaptic dopa-
minergic D2 receptors in the brain. It may also have effects 
by binding D1 dopamine, 5-HT2 serotonin, H1 histamine, 
and alpha2 adrenergic receptors in the central nervous 
system.30,31 The use of butyrophenones for analgesia dates 
back to the 1970s.32,33 It is believed that haloperidol exerts 
analgesic effects and synergistic analgesic effects, through 
the modulation of NMDA-receptors as well as sigma-1 
receptors.34–36 After a single dose of 3 mg haloperidol, 
sigma-1 receptor antagonists will mimic opioid efficacy 
by blocking pain perception without unwanted opioid side 
effects.37 It has also been suggested that they decrease pain 
sensitivity via NMDA inhibition, thereby inhibiting the 
pain wind-up and opioid hyperalgesia phenomenon.38,39 
Droperidol has some additional mechanisms of action; 
however, we will defer this discussion as the drug is not 
currently clinically available.
Haloperidol is metabolized by CYP 3A4, 1A2, and 
2D6, therefore drug interactions will arise with any other 
medication that would induce or inhibit these hepatic 
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rifampin.40,41  Common side effects from short-term halo-
peridol  administration include sedation and anticholinergic 
effects. Less common effects include orthostatic hypoten-
sion and tachycardia, although hypotension is less common 
with haloperidol than droperidol due to less alpha blocking 
effect.42 Uncommon adverse effects include pruritis, diar-
rhea, and electrocardiogram changes. QT-prolongation is a 
known side effect, thus concurrent administration with other 
QT-prolonging medications in patients with a prolonged QT 
or electrolyte abnormalities (low potassium or magnesium) 
should be avoided to prevent dysrhythmia (most notably 
torsades de pointes).41 Coadministration with other neuro-
leptics or dopaminergic agents may precipitate extrapyra-
midal symptoms and possibly even neuroleptic malignant 
syndrome.31,41
Whether all butyrophenones have similar analgesic quali-
ties is not known as there are no studies that directly compare 
individual butyrophenones with each other. However, several 
Table 1 Marketed butyrophenones with approval status and indication
Generic 
name
Trade name Approved for 
human use?
Approved for 
use in the USA?
Notes
Azaperone Azaperona, Stresnil, Fluoperidol, 
Suicalm, eucalmyl, Sedaperone 
vet
No Yes Approved for veterinary use only
Benperidol Anquil, Glianimon Yes No Most potent neuroleptic on the european 
market; 150%–200% potency of haloperidol
Bromperidol Brimidol, Bromodol, erodium, 
impromen
Yes No Only available in Belgium, German, the 
Netherlands, and italy
Cinuperone Yes No  
Droperidol Droleptan, Dridol, inapsine, 
Xomolix, innovar (combination 
with fentanyl)
Yes Yes US FDA Black Box warning for torsade’s de 
pointesa
Fluanisone Haloanison, Sedalande, Anti-Pica, 
Metorin
Yes No veterinary use; used for agitation in humans, but 
no longer marketed; was available in Belgium, 
France, Germany, and Switzerland
Haloperidol Haldol, Peridol Yes Yes  
Lenperone elanone-v Yes No veterinary use
Moperone Luvatren, Methylperidol, 
Meperon, Luvatrena
Yes No No longer available on market. Previously 
available in Japan, Sweden, and Switzerland
Nonaperone Nonaperonum, Nonaperona Yes No Only available in india.
Pipamperone Dipiperone, Dipiperal, Piperonil, 
Piperonyl, Propitan
Yes No Also known by non-trade names including 
carpiperone and floropipamide or fluoropipamide, 
and as floropipamide hydrochloride
Spiperone Spiroperidol, Spiropitan Yes No Marketed in Japan
Timiperone Tolopelon Yes No Marketed in Japan
Trifluperidol Psychoperidol, Triperidol, 
Trisedyl
Yes No Only available in india. Previously available in 
Belgium, France, Germany, italy, and the UK
Notes: ain 2001, the US FDA changed the labeling requirements for droperidol injection to include a Black Box warning, citing concerns of QT prolongation and torsades de 
pointes. The evidence for this is disputed, with nine reported cases of torsades de pointes in 30 years and all of those having received doses more than 5 mg. QT prolongation 
is a dose-related effect, and it appears that droperidol is not a significant risk in low doses. A study in 2015 showed that droperidol is relatively safe and effective for the 
management of violent and aggressive adult patients in hospital emergency departments in doses of 10 mg and above and that there was no increased risk of QT prolongation 
and torsades de pointes.
Abbreviation: US FDA, United States Food and Drug Administration.
studies have demonstrated clinically significant pain relief 
and/or decreased opioid consumption with the administration 
of haloperidol and droperidol.30,43–45 In healthy volunteers, 
droperidol potentiated analgesic effects of fentanyl.46 Trials 
of ED patients with abdominal pain have shown that halo-
peridol may improve analgesia and reduce opiate consump-
tion, nausea, and admission rates.34,47–53 Similarly, droperidol 
has been shown to reduce pain in patients presenting with 
biliary colic,54 postoperative patients following urologic pro-
cedures,55 and during gastrointestinal endoscopy.56,57 Several 
studies have reported improvements in postoperative pain 
and reduced opiate consumption with both haloperidol and 
droperidol.58–60 Moreover, haloperidol has shown efficacy in 
patients with chronic abdominal pain,61 chronic functional 
intestinal disorders,62 and pain in the setting of opiate depen-
dence.47 The onset of action of haloperidol and droperidol 
is within 20 and 10 minutes, respectively, both with peaks 
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is from 0.5 to 3 hours post-administration.31 Although toler-
ance to haloperidol has been described for catalepsy and 
 behavioral effects, butyrophenone drug tolerance for pain has 
not been reported.59 The dosing of haloperidol is typically 5 
mg. One study found no additional benefit for postoperative 
pain for Haldol 10 mg over 5 mg dosing.63 Whether admin-
istration route alters efficacy is unclear.
why it is important to do this review?
In the late 1990s, the medical community began to prescribe 
opioids at a greater rate, in part due to advertising and mis-
guidance from pharmaceutical companies coupled with the 
public awareness of health care failure to adequately address 
pain.64,65 This spurred a widespread misuse of opioids, includ-
ing prescription drugs, heroin, and synthetics. According to 
the Centers for Disease Control and Prevention, there was a 
quadrupling in the number of opioid prescriptions from 1999 
to 2010, with a corresponding quadrupling of opioid-related 
deaths over the same period.65 The link between prescribing 
rates and overdose deaths appears to be directly related to 
maximum prescribed daily doses and not to regularly sched-
uled and as-needed doses.65
This is not to say that opioid analgesics do not serve an 
important role in the treatment of acute and chronic pain, 
but misuse has become a public health crisis. The USA has 
become the prescriber of 80% of global prescribed narcot-
ics; ≥50 times more than the rest of the world combined.66,67 
Nearly 25% of prescribed opioid users misuse their prescrip-
tion, and 115 Americans die daily from opioid overdose.68–70 
Global consumption of opioids has more than tripled over the 
past 20 years with a majority of use in North America and 
Europe.71 Opiates comprise 58% of analgesic use in the ED,5 
with abdominal pain accounting for 10%–44% of ED opioid 
administration.4,72–75 Administration of opioids (with later 
prescription) in the ED has been linked to an increased risk 
of becoming a recurrent opioid user.72 Identifying safe and 
effective analgesia techniques that limit narcotic consump-
tion and prescription is needed. We investigated the evidence 
for using neuroleptanalgesia as an effective opioid sparing 
alternative to analgesia in patients with AAP.
Objectives
The objective of this systematic review was to address the 
following research question: in patients with AAP (popula-
tion), does administration of butyrophenone antipsychotics 
(intervention) compared to placebo, usual care, or opiates 
alone (comparisons) improve analgesia and decrease opiate 
consumption (outcomes)?
Methods
This systematic review followed the steps outlined in the 
PRISMA. A systematic review protocol was developed 
before conducting the project. The systematic review 
was registered at the International prospective register of 
systematic reviews (PROSPERO, registration number: 
CRD42018104226).
Criteria for considering studies for this 
review
Types of studies
Prospective randomized trials were included.
Types of participants
Adult patients being treated for AAP in the ED, intensive care 
unit (ICU), or immediate postoperative setting were included.
Types of interventions
We assessed the analgesic effects of butyrophenone (halo-
peridol, droperidol) antipsychotics administered by either 
intravenous or intramuscular route. For all endpoints with 
available data, we compared 1) butyrophenone alone vs 
placebo or conventional therapy, 2) butyrophenone alone 
vs opiate alone, and 3) butyrophenone plus opiate vs opiate 
alone. For selected variables (eg, opiate consumption), we 
also analyzed the following data separately: 1) ED patients 
only and 2) postoperative patients only.
Outcome measures
Primary outcomes
The primary outcomes included 1) adequate pain control 
using any validated pain scale used by the original tri-
als and 2) opiate consumption (milligrams of morphine 
sulfate or morphine equivalents) administered to achieve 
pain control.
Secondary outcomes
The secondary outcomes were 1) patient satisfaction with 
analgesia, 2) admission rates for ED patients, 3) ED LOS, 4) 
hospital LOS, and 5) side effects (extrapyramidal, akathisia, 
and cardiac).
Search methods for the identification of 
studies
electronic searches
A librarian who was specialized in systematic reviews and 
meta-analysis developed a structured search strategy for 
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Reviews of Effects (DARE), Directory of Open Access Jour-
nals (DOAJ), Embase, IEEE-Xplorer, Latin American and 
Caribbean Health Sciences Literature (LILACS), Magiran, 
PubMed, Scientific Information Database (SID), Scopus, 
TÜBİTAK ULAKBİM, and Web of Science. Bibliographies 
of the relevant articles were also searched. The searches were 
not limited by date, language, or publication status.
Searching other resources
To limit publication bias, searches were conducted in Clinical-
Trials.gov website, World Health Organization International 
Clinical Trials Registry Platform (WHO ICTRP), and the 
Australian New Zealand Clinical Trials Registry (ANZCTR). 
Abstracts of the conference proceedings of the relevant 
disciplines were also searched (past 5 years) to identify any 
presented but not published abstracts. We also contacted the 
experts in the field and inquired about the possible ongoing 
trials that might not have been identified in our search. Unpub-
lished or “in press” trials that met inclusion criteria were eli-
gible for inclusion if only the authors responded to inquiry from 
ACM with requested primary data sets or unpublished results.
Selection of studies
Three authors (ACM, AMK, and AACB) reviewed the titles 
and abstracts to determine eligibility for inclusion based on 
relevance. Studies eligible for inclusion were prospective and 
randomized clinical trials enrolling patients with AAP treated 
in acute care environments (ED, ICU, and postoperative). The 
butyrophenone of interest must have been administered by either 
the IV or intramuscular route. Acceptable comparison groups 
included placebo, opiate only, corticosteroids, non-steroidal 
anti-inflammatory drugs, or acetaminophen. The full articles of 
relevant abstracts were obtained and reviewed in their entirety.
Data extraction and management
Reference management and application of inclusion/exclu-
sion criteria was performed with Rayyan (Qatar Computing 
Research Institute, Ar-Rayyan, Qatar; https://rayyan.qcri.org/). 
Three authors applied inclusion exclusion criteria (ACM, AMK, 
and YM). Four review authors (ACM, AMK, AACB, and YM) 
extracted data onto a pre-designed structured data extraction 
forms. Any disagreements were resolved by consensus. We 
arranged translation of any papers by experts where necessary.
Assessment of reporting biases and quality 
assessment
Three review authors (AMK, AACB, and YM) indepen-
dently assessed the risk of bias using two validated tools: 
Grading of Recommendations, Assessment, Development 
and Evaluations (GRADE),76 and RoB 2.0: “Revised tool 
for Risk of Bias in randomized trials”.77 ACM reviewed the 
Risk of Bias assessments. The review authors considered 
methods of randomization and allocation, blinding (of 
treatment administrator, participants, and outcome asses-
sors), selective outcome reporting (eg, failure to report 
adverse events), and incomplete outcome data. Each trial 
was graded as high, low, or unclear risk of bias for each 
of these criteria.
Because of the clinical and statistical heterogeneity of the 
studies, the intended meta-analysis was omitted.
Results
Description of studies
Results of the search
We identified 7,217 references from the following sources: 
Cochrane CENTRAL (n=108), CINAHL (n=129), DARE 
(n=5), DOAJ (n=25), Embase (n=4850), IEEE-Xplorer 
(n=149), LILACS (n=87), Magiran (n=10), PubMed (n=925), 
SID (n=22), Scopus (n=722), TÜBİTAK ULAKBİM (n=0), 
and Web of Science (n=185). We found no ongoing stud-
ies in the Clinicaltrials.gov, WHO ICTRP, or ANZCTR. 
No ongoing studies were identified in Clinicaltrials.gov, 
WHO ICTRP, or ANZCTR. Figure 1 shows the PRISMA 
flow diagram, and the Supplementary material provides the 
search strategy.
included studies
Six studies met the inclusion criteria and are summarized in 
Tables 2 and 3.78–83 One study assessed patients presenting 
to the ED with AAP associated with gastroparesis,83 whereas 
five studies assessed patients with abdominal pain following 
abdominal surgery: abdominal hysterectomy (n=4)79–82 and 
sleeve gastrectomy (n=1).78
excluded studies
Excluded references assessing neuroleptanalgesia for 
abdominal pain included three case reports,48,49,61 three case 
series,54,59,84 and one non-randomized controlled trial.61 
Ramirez et al34 was excluded as it had a retrospective cohort 
design. Three studies assessed pain in mixed populations, 
including abdominal, but data for abdominal pain patients 
was not listed independently.38,47,85 Bertrand et al55 was 
excluded as they did not clearly describe which urologic pro-
cedures were included or whether they were intra-abdominal. 
Lamond et al58 was excluded due to lack of a morphine only, 
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assessed the effect of butyrophenones for abdominal pain 
administered neither intravenously or intramuscularly were 
excluded: epidural, extradural, or intrathecal;86–94 subcutane-
ous;95 or oral.96
Risk of bias in included studies
We have summarized our risk of bias and GRADE assess-
ments in Figure 2 and Table 4.
Allocation (selection bias)
Four studies were at low risk of selection bias, being 
adequately randomized with allocation concealment.78,80,81,83 
Among the remaining studies, the risk of bias from the 
method of randomization was unclear,79 and the risk of bias 
for allocation concealment was unclear or high.79,82
Blinding (performance bias and detection bias)
Four studies were double-blinded.78,80,81,83 Although all six 
studies had a control arm, only one was a placebo controlled 
trial.83 One study reported “double-blind”, but the methods 
of concealment and blinding were not described in the 
manuscript, so it was marked as unclear.82 One article did 
not describe blinding or placebo use.82
incomplete outcome data (attrition bias)
Two studies reported no patient attrition.78,79 One study 
reported <10% attrition,81 whereas one reported a rate of 
16% for attrition.82 Two studies did not report patient attri-
tion data.80,83
Selective reporting (reporting bias)
All included studies reported their intended primary out-
comes. One study did not report adverse events.78
Other potential sources of bias
Diagnostic criteria
All included studies gave adequate information, namely that 
patients were diagnosed with AAP.78–83
Outcome criteria
Five studies assessed pain intensity. Three used a VAS 
(1–10),79,80,83 while two used a verbal rating scale (VRS; 
1–10).78,81 Five studies assessed opiate consumption in terms 
of milligrams of morphine78,79,81,82 or tramadol80 consumed. 
Patient satisfaction with analgesia was reported in two studies 
using a 5-point scoring system.82,83
Statistical analysis
Five of the six included trials provided adequate details; 
they clearly stated the statistical tests used, which appeared 
appropriate.78–81,83 One trial was market “unclear” as it did 
not state the tests used.82
Baseline differences between groups
In five of the six trials, the provided information were ade-
quate in this category.78–81,83 No significant differences were 
observed between treatment groups for these studies. One 
study scored “unclear” in this category as it did not clearly 
describe differences between groups.82
Figure 1 PRISMA flow diagram.




Full-text articles excluded (n=28)
Full-text articles assessed for eligibility (n=34)
Studies included in qualitative synthesis (n=6)
































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1




















USA; 2 hospitals; 
emergency 
department; adult 




Haloperidol 5 mg iM 
(single dose)
Placebo (single dose) 
+ Conventional 
therapy
Pain intensity measured 

















PCA (no basal 
infusion) with bolus 
of Morphine 1 mg + 
droperidol 0.05 
mg, and 5 minutes 
lockout (continued 
for 24 hours)
PCA (no basal 
infusion) with bolus 
of Morphine 1 




defined by mg of 



















Post-op PCA of 
morphine (1.0 mg) 
plus cyclizine (2 mg). 
No basal infusion, 
6-minute lock-out, 4 
hours max morphine 
sulfate dose of 30 
mg (continued for 48 
hours)
Post-op PCA of 
morphine (1.0 mg) 
plus droperidol 
(0.05 mg). No basal 
infusion, 6-minute 
lock-out, 4 hours 
max morphine sulfate 
dose of 30 mg. 
(continued for 48 
hours)
Pain intensity measured 
by 10 cm visual analog 
scale
















PCA (no basal 
infusion) with bolus 
of tramadol 20 mg + 
droperidol 0.1 mg; 
10-minute lockout 
(continued for 36 
hours)
PCA (no basal 
infusion) with bolus 
of tramadol 20 mg; 
10-minute lockout. 
(continued for 36 
hours)
1. Pain intensity 




by mg of morphine 














PCA (no basal 
infusion) with bolus 
of morphine 1 mg + 
droperidol 0.05 mg. 
5-minuite lockout. 4 
hours morphine max 
of 30 mg (continued 
for 72 hours)
PCA (no basal 
infusion) with bolus 
of morphine 1 mg. 
5-minuite lockout. 4 
hours morphine max 
of 30 mg (continued 
for 72 hours)
1. Pain intensity 
measured by a 




by mg of morphine 




















Ondansetron 8 mg 
iv + dexamethasone 
8 mg + haloperidol 2 
mg (single dose)
Ondansetron 8 mg iv
Ondansetron 8 mg 
iv + dexamethasone 
8 mg iv
(both single dose)
1. Nausea defined by 
a 10-point verbal 
numerical scale
2. Pain intensity defined 




defined by mg of 
morphine received 
over 36 hours 
post-op































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1









Study Roldan (2017)83 Sharma (1993)82 Laffey (2002)79 Liu (2003)80 Lo (2005)81 Oliviera (2013)78
Butyrophenone Haloperidol Droperidol Droperidol Droperidol Droperidol Haloperidol
Comparison Standard care Morphine Morphine Tramadol Morphine Dexamethasone
Ondansetron
Pain intensity ↓   NC ↓ ↓a
Patient satisfaction NC ↑     
Opiate consumption  NC NC NC ↓ ↓
eD admission ↓      
eD LOS NC      
extrapyramidal side 
effects
 NC NC  NC  










Sedation  NC NC NC   
Notes: NC means no change. aThe Haldol + dexamethasone + ondansetron group had improved pain scores compared to ondansetron alone (P=0.046), but no change 
compared to dexamethasone + ondansetron group (P=0.052).
Figure 2 Risk of bias assessment. 
Notes: + signifies low risk; ? signifies uncertain risk; – signifies high risk.
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We detected significant differences in clinical settings, 
inclusion/exclusion criteria, and quality of the trials. Due 
to high level of clinical heterogeneity, we determined that 
pooling the data and performing a meta-analysis would not 
be appropriate.
effects of interventions
An overview of results is presented in Table 3. Three of 
four studies found improvements in pain intensity in the 
butyrophenone group. Three of five studies reporting post-
operative opiate consumption reported no change,79,80,82 while 
two reported a decrease in opiate consumption.78,81 One ED 
study reported no change in patient satisfaction,83 while one 
postoperative study reported improvement in satisfaction 
scores.82 Extrapyramidal side effects79,81,82 and sedation79,80,82 
were both reported as unchanged in three studies each.
Discussion
Summary of main results
Six RCTs (538 participants) that met the inclusion criteria 
were identified. Neuroleptanalgesia was associated with 
improved pain control (three of four studies); however, only 
two studies compared the strategy to an opiate-only group 
(morphine, n=1; tramadol, n=1).78,80,81,83 Opiate consump-
tion was reported in five postoperative studies (no change 
[n=3],79,80,82 decreased [n=2]).78,81 One ED study reported no 
change in patient satisfaction,83 while one postoperative study 
Table 4 GRADe quality of evidence ratings
 Certainty assessment Certainty
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Notes: aTwo study drugs were assessed: haloperidol (two studies) and droperidol (three studies). Significant variability existed in control groups: conventional therapy (one 
study), morphine plus cyclizine (one study), tramadol (one study), morphine alone (one study), and dexamethasone and ondansetron (one study). bSmall number of studies 
resulting in likely type ii error. Absence of negative or neutral studies suggests evidence of publication bias. cRisk of bias high in one study, low in three studies. dThe study 
was judged to have a high risk of bias. eOne study at high risk, one study at moderate risk, and one study at low risk for bias.
Abbreviations: eD, emergency department; GRADe, Grading of Recommendations, Assessment, Development and evaluations.
reported improvement in satisfaction scores.82 Extrapyrami-
dal side effects79,81,82and sedation79,80,82 were both reported as 
unchanged in three studies each.
Overall completeness and applicability of 
evidence
There are some caveats that should be considered before 
drawing any conclusions from the findings of this systematic 
review. The small number of studies identified, of which all 
are positive, suggest both a high risk for publication bias and 
possibly type I error.
Heterogeneity may be due to clinical variation, for 
example, in study participation characteristics, baseline 
disease severity, delay in receiving treatment, different 
treatment used, and small numbers. For example, the mean 
age of included studies ranged from 32 to 58 years. It is 
unclear how this relatively young patient demographic 
influenced the findings. Conversely, included studies rep-
resent a mixture of resource-rich and -poor environments, 
with one study each from Brazil, China, England, Ireland, 
Taiwan, and the USA.
In addition, variation may be due to methodological 
considerations such as method of randomization, the use 
of blinding, the choice of outcome assessment measures, 
and trial duration. In particular, the trial by Sharma et al 
had methodological weaknesses in allocation concealment, 
blinding (participants and personnel), blinding of outcome 
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Heterogeneity was less notable in the postoperative 
studies as the inclusion criteria were narrow. Only one ED 
study was included. Clinical heterogeneity (different pain 
assessment scales used) and methodological heterogeneity 
(different treatment regimens and follow-up plans) limit the 
interpretation of these data. We found variation in the clinical 
endpoints chosen as defining improved analgesia: three trials 
reported VAS,79,80,83 two reported VRS,78,81 and two reported 
patient satisfaction with analgesia scores.82,83 Whereas the 
differences in symptoms at recruitment are likely minimal 
for the postoperative trials, it is unclear whether a difference 
existed between the ED and postoperative trials.
Quality of evidence
We downgraded the quality of evidence for the trial by Sharma 
et al for concerns for potential selection bias, performance 
bias, detection bias, attrition bias, reporting bias, and not 
describing a sample size calculation. The quality of evidence 
was also downgraded for the trial by Laffey et al because 
of concerns for potential selection bias (random sequence 
generation and allocation concealment) and attrition bias.
Potential biases in the review process
We excluded several studies and a published abstract that 
provided insufficient information. One abstract50 seemed to 
duplicate information available in a subsequent published 
manuscript.83 One study was excluded because the published 
manuscript did not differentiate patients with abdominal 
pain from those with extremity pain.47 Attempts to contact 
the author for results on the abdominal pain patients did 
not receive response. As a result, there could be some risk 
of publication and selective reporting bias due to data from 
some studies being unavailable.
Lastly, we included studies conducted in Asia, North 
and South America, and Europe. It is possible that genetic 
differences in drug metabolism or response or even different 
etiological processes may account for some of the observed 
variation in response.
Agreements and disagreements with 
other studies or reviews
We identified no other systematic reviews or meta-analyses 
on this topic for comparison.
Conclusion
implications for practice
Based on available evidence, we cannot draw any definitive 
conclusion on the efficacy or benefit of neuroleptanalgesia 
in the management of patients with AAP. However, the exist-
ing data suggest that these drugs may improve analgesia and 
decrease opiate consumption.
implications for research
Additional clinical study is needed to assess the utility of 
neuroleptanalgesia for decreasing pain and opiate consump-
tion of patients in acute care settings with abdominal pain 
from gastroparesis, cyclical vomiting syndrome, cannabinoid 
hyperemesis, and other forms of AAP.
Differences between protocol and 
review
The presence of significant methodological differences 
between studies precluded the performance of a meta-
analysis. Therefore, only the systematic review portion of 
the project is presented in this manuscript.
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Combined search for butyrophenones
“Butyrophenones”[Mesh] OR “acetabutone” [Supplementary 
Concept] OR “Azaperone”[Mesh] OR “Benperidol”[Mesh] 
OR “bromperidol” [Supplementary Concept] OR “bromperi-
dol decanoate” [Supplementary Concept] OR “4-bromospi-
perone” [Supplementary Concept] OR “Droperidol”[Mesh] 
OR “fluanisone” [Supplementary Concept] OR “butofilolol” 
[Supplementary Concept] OR “carebastine” [Supplementary 
Concept] OR “centbutindole” [Supplementary Concept] OR 
“clofluperol” [Supplementary Concept] OR “Droperidol” 
[Mesh] OR “ebastine” [Supplementary Concept] OR “flua-
nisone” [Supplementary Concept] OR “Haloperidol”[Mesh] 
OR “ketocaine” [Supplementary Concept] OR “lenperone” 
[Supplementary Concept] OR “metylperon” [Supplementary 
Concept] OR “moperone” [Supplementary Concept] OR 
“pipamperone” [Supplementary Concept] OR “setoperone” 
[Supplementary Concept] OR “Spiperone”[Mesh] OR 
“spiramide” [Supplementary Concept]) OR “timiperone” 
[Supplementary Concept]) OR “Trifluperidol”[Mesh] 
OR Butyrophenone[tiab] OR Butyrophenones[tiab] OR 
Aceperone[tiab] OR Acetabutone[tiab] OR Acetobutone[tiab] 
OR Azaperone[tiab] OR Butanone[tiab] OR Sedaperone[tiab] 
OR Stresnil[tiab] OR Benperidol[tiab] OR Benperidone[tiab] 
OR Benzperidol[tiab] OR Frenactyl[tiab] OR Phenactil[tiab] 
OR Anquil[tiab] OR Frenactil[tiab] OR Glianimon[tiab] 
OR Bromperidol[tiab] OR Bromoperidol[tiab] OR 
Impromen[tiab] OR Tesoprel[tiab] OR Erodium[tiab] OR 
Bromospiperone[tiab] OR Bromospiroperidol[tiab] OR 
Butofilolol[tiab] OR cafide[tiab] OR Carebastine[tiab] OR 
Centbutindole[tiab] OR Indole[tiab] OR Cinuperone[tiab] 
OR Clofluperol[tiab] OR seperidol[tiab] OR Droperidol[tiab] 
OR Dridol[tiab] OR Droleptan[tiab] OR Droperol[tiab] 
OR Halkan[tiab] OR Inaprine[tiab] OR Inapsin[tiab] OR 
Inapsine[tiab] OR Oridol[tiab] OR Sintodian[tiab] OR 
Troperidol[tiab] OR Xomolix[tiab] OR Ebastine[tiab] OR 
Bactil[tiab] OR bastel[tiab] OR busidril[tiab] OR ebachoi[tiab] 
OR ebarren[tiab] OR ebastel[tiab] OR ebonde[tiab] OR 
ebontan[tiab] OR ebouda[tiab] OR evastel[tiab] OR 
kestin[tiab] OR kestine[tiab] OR “nosedat”[tiab] OR 
nosedat[tiab] OR oroba[tiab] OR Fluanisone[tiab] OR 
Hypnorm[tiab] OR “anti pica”[tiab] OR antipica[tiab] OR 
fluanison[tiab] OR fluanisone dihydrochloride[tiab] OR 
fluanizone[tiab] OR fluoanisone[tiab] OR haloanison[tiab] OR 
haloanisone[tiab] OR haloanizone[tiab] OR sedalande[tiab] 
OR sedalanide[tiab] OR solusediv[tiab] OR Fluspiperone[tiab] 
OR Haloperidol[tiab] OR alased[tiab] OR aloperidin[tiab] 
OR aloperidine[tiab] OR binison[tiab] OR brotopon[tiab] 
OR celenase[tiab] OR cereen[tiab] OR cerenace[tiab] OR 
cizoren[tiab] OR depidol[tiab] OR dores[tiab] OR dozic[tiab] 
OR duraperidol[tiab] OR fortunan[tiab] OR govotil[tiab] 
OR haldol[tiab] OR halidol[tiab] OR “halo-p”[tiab] OR 
halojust[tiab] OR halomed[tiab] OR haloneural[tiab] OR 
haloper[tiab] OR haloperil[tiab] OR haloperin[tiab] OR 
haloperitol[tiab] OR halopidol[tiab] OR halopol[tiab] 
OR halosten[tiab] OR haricon[tiab] OR haridol-d[tiab] 
OR keselan[tiab] OR linton[tiab] OR mixidol[tiab] OR 
novoperidol[tiab] OR peluces[tiab] OR perida[tiab] OR 
peridol[tiab] OR peridor[tiab] OR selezyme[tiab] OR 
seranace[tiab] OR serenace[tiab] OR serenase[tiab] OR 
serenelfi[tiab] OR siegoperidol[tiab] OR sigaperidol[tiab] OR 
Ketocaine[tiab] OR Lenperone[tiab] OR elanone[tiab] OR 
Lumateperone[tiab] OR Tosylate[tiab] OR Melperone[tiab] 
OR bunil[tiab] OR buronil[tiab] OR eunerpan[tiab] OR 
flubuperone[tiab] OR harmosin[tiab] OR melneurin[tiab] OR 
melperomerck[tiab] OR melperon[tiab] OR methylperon[tiab] 
OR methylperone[tiab] OR metylperone[tiab] OR 
metylperonum[tiab] OR Moperone[tiab] OR Libernil[tiab] OR 
luvatren[tiab] OR luvatrena[tiab] OR “methyl peridol”[tiab] 
OR methylperidol[tiab] OR methylperidole[tiab] OR 
moperon[tiab] OR Perfomedil[tiab] OR Pipamperone[tiab] 
OR car p iperone[ t iab]  OR dipeperon[ t iab]  OR 
dipiperon[tiab] OR “dl piperonyl”[tiab] OR dipiperal[tiab] 
OR floropipamide[tiab] OR flouropipamide[tiab] OR 
piperonil[tiab] OR piperonyl[tiab] OR pripamperone[tiab] 
OR propitan[tiab] OR Setoperone[tiab] OR Spiperone[tiab] 
OR Spiroperidol[ t iab]  OR Spiropi tan[t iab]  OR 
Spiramide[tiab] OR “AMI-193”[tiab] OR Timiperone[tiab] 
OR tolopelon[tiab] OR Trifluperidol[tiab] OR triperidol[tiab] 
OR psicoperidol[tiab] OR trisedil[tiab] OR trisedyl[tiab].
Combined search for abdominal pain
Version 1: Combined MeSH terms for pain, postop pain, 
and acute pain with terms for abdomen and GI tract, without 
including all the MeSH terms nested under “pain”.
“A b d o m i n a l  Pa i n ” [ M e s h ]  O R  “A b d o m e n , 
Acute”[Mesh] OR “Irritable Bowel Syndrome”[Mesh] 
OR “Colonic Diseases”[Mesh] OR “Dyspepsia”[Mesh] 
OR “Gastroparesis”[Mesh] OR ((“Abdomen”[Mesh] OR 
“Digestive System”[Mesh]) AND (“Acute Pain”[Mesh] OR 
“Pain”[Mesh:NoExp] OR “Pain, Postoperative”[Mesh])) OR 
((Abdomen[tiab] OR Abdomens[tiab] OR Abdominal[tiab] 
OR Intestine[tiab] OR Intestines[tiab] OR Intestinal[tiab] 
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OR Bowel[tiab] OR Bowels[tiab] OR Belly[tiab] OR 
Gastrointestinal[tiab] OR Gastric[tiab] OR “gi tract”[tiab] 
OR “gi tracts”[tiab] OR epigastric[tiab] OR Stomach[tiab] 
OR Stomachs[tiab]) AND (Pain[tiab] OR Pains[tiab] OR 
Painful[tiab] OR Ache[tiab] OR Aches[tiab] OR Achy[tiab] 
OR Aching[tiab] OR Cramp[tiab] OR Cramps[tiab] OR 
Discomfort[tiab] OR discomforting[tiab] OR Suffering[tiab] 
OR Sufferings[tiab] OR Agony[tiab] OR agonizing[tiab] 
OR Distress[tiab] OR Distressful[tiab] OR Spasm[tiab] OR 
Spasms[tiab] OR Paroxysm[tiab] OR paroxysms[tiab])) 
OR Gastroparesis[tiab] OR “gastric stasis”[tiab] OR 
Dyspepsia[tiab] OR Dyspeptic[tiab] OR Dyspepsias[tiab] 
OR “Irritable bowel syndrome”[tiab].
Version 2: Took off the ‘Mesh:NoExp’ from term 
“Pain”[Mesh]: yielded 553 articles when combined with 
butyrophenones terms.
“A b d o m i n a l  Pa i n ” [ M e s h ]  O R  “A b d o m e n , 
Acute”[Mesh] OR “Irritable Bowel Syndrome”[Mesh] 
OR “Colonic Diseases”[Mesh] OR “Dyspepsia”[Mesh] 
OR “Gastroparesis”[Mesh] OR ((“Abdomen”[Mesh] OR 
“Digestive System”[Mesh]) AND (“Acute Pain”[Mesh] 
OR “Pain”[Mesh] OR “Pain, Postoperative”[Mesh])) OR 
((Abdomen[tiab] OR Abdomens[tiab] OR Abdominal[tiab] 
OR Intestine[tiab] OR Intestines[tiab] OR Intestinal[tiab] 
OR Viscera[tiab] OR Visceral[tiab] OR Tummy[tiab] 
OR Bowel[tiab] OR Bowels[tiab] OR Belly[tiab] OR 
Gastrointestinal[tiab] OR Gastric[tiab] OR “gi tract”[tiab] 
OR “gi tracts”[tiab] OR epigastric[tiab] OR Stomach[tiab] 
OR Stomachs[tiab]) AND (Pain[tiab] OR Pains[tiab] OR 
Painful[tiab] OR Ache[tiab] OR Aches[tiab] OR Achy[tiab] 
OR Aching[tiab] OR Cramp[tiab] OR Cramps[tiab] OR 
Discomfort[tiab] OR discomforting[tiab] OR Suffering[tiab] 
OR Sufferings[tiab] OR Agony[tiab] OR agonizing[tiab] 
OR Distress[tiab] OR Distressful[tiab] OR Spasm[tiab] OR 
Spasms[tiab] OR Paroxysm[tiab] OR paroxysms[tiab])) 
OR Gastroparesis[tiab] OR “gastric stasis”[tiab] OR 
Dyspepsia[tiab] OR Dyspeptic[tiab] OR Dyspepsias[tiab] 
OR “Irritable bowel syndrome”[tiab].
Took off the “no explosion” from Mesh term for pain: 
yielded 772 results when combined with butyrophenones 
terms; 560 articles when animal studies removed.
“Acute Pain”[Mesh] OR “Pain”[Mesh] OR “Abdominal 
Pain”[Mesh] OR “Abdomen, Acute”[Mesh] OR “Irritable 
Bowel Syndrome”[Mesh] OR “Colonic Diseases”[Mesh] 
OR “Dyspepsia”[Mesh] OR “Gastroparesis”[Mesh] OR 
((Abdomen[tiab] OR Abdomens[tiab] OR Abdominal[tiab] 
OR Intestine[tiab] OR Intestines[tiab] OR Intestinal[tiab] 
OR Viscera[tiab] OR Visceral[tiab] OR Tummy[tiab] 
OR Bowel[tiab] OR Bowels[tiab] OR Belly[tiab] OR 
Gastrointestinal[tiab] OR Gastric[tiab] OR “gi tract”[tiab] 
OR “gi tracts”[tiab] OR epigastric[tiab] OR Stomach[tiab] 
OR Stomachs[tiab]) AND (Pain[tiab] OR Pains[tiab] OR 
Painful[tiab] OR Ache[tiab] OR Aches[tiab] OR Achy[tiab] 
OR Aching[tiab] OR Cramp[tiab] OR Cramps[tiab] OR 
Discomfort[tiab] OR discomforting[tiab] OR Suffering[tiab] 
OR Sufferings[tiab] OR Agony[tiab] OR agonizing[tiab] 
OR Distress[tiab] OR Distressful[tiab] OR Spasm[tiab] 
OR Spasms[tiab] OR Paroxysm[tiab] OR paroxysms[tiab] 
OR paroxysmal[tiab])) OR Gastroparesis[tiab] OR “gastric 
stasis”[tiab] OR Dyspepsia[tiab] OR Dyspeptic[tiab] OR 
Dyspepsias[tiab] OR “Irritable bowel syndrome”[tiab].
Added in terms for abdomen and GI tract: yielded 2,489 
articles when combined with butyrophenones terms; 772 
when animal studies removed.
“A b d o m i n a l  Pa i n ” [ M e s h ]  O R  “A b d o m e n , 
Acute”[Mesh] OR “Irritable Bowel Syndrome”[Mesh] 
OR “Colonic Diseases”[Mesh] OR “Dyspepsia”[Mesh] 
OR “Gastroparesis”[Mesh] OR “Abdomen”[Mesh] OR 
“Digestive System”[Mesh] OR “Acute Pain”[Mesh] OR 
“Pain”[Mesh:NoExp] OR “Pain, Postoperative”[Mesh] OR 
((Abdomen[tiab] OR Abdomens[tiab] OR Abdominal[tiab] 
OR Intestine[tiab] OR Intestines[tiab] OR Intestinal[tiab] 
OR Viscera[tiab] OR Visceral[tiab] OR Tummy[tiab] 
OR Bowel[tiab] OR Bowels[tiab] OR Belly[tiab] OR 
Gastrointestinal[tiab] OR Gastric[tiab] OR “gi tract”[tiab] 
OR “gi tracts”[tiab] OR epigastric[tiab] OR Stomach[tiab] 
OR Stomachs[tiab]) AND (Pain[tiab] OR Pains[tiab] OR 
Painful[tiab] OR Ache[tiab] OR Aches[tiab] OR Achy[tiab] 
OR Aching[tiab] OR Cramp[tiab] OR Cramps[tiab] OR 
Discomfort[tiab] OR discomforting[tiab] OR Suffering[tiab] 
OR Sufferings[tiab] OR Agony[tiab] OR agonizing[tiab] 
OR Distress[tiab] OR Distressful[tiab] OR Spasm[tiab] 
OR Spasms[tiab] OR Paroxysm[tiab] OR paroxysms[tiab] 
OR paroxysmal[tiab])) OR Gastroparesis[tiab] OR “gastric 
stasis”[tiab] OR Dyspepsia[tiab] OR Dyspeptic[tiab] OR 
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